Targeted therapy against ALK alterations use tyrosine kinase inhibitors (TKIs) to treat ALK-positive tumors, most notably in non-small cell lung cancer (NSCLC) (Fukui et al., 2022). This evidence concerns the gene ALK and non-small cell lung carcinoma.